» Articles » PMID: 16201907

Biomembrane-permeable and Ribonuclease-resistant SiRNA with Enhanced Activity

Overview
Date 2005 Oct 6
PMID 16201907
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Small interfering RNAs (siRNA) could be the ideal inhibitor of specific gene expression if they could be delivered efficiently to their targets. Although siRNAs cannot by themselves cross cell membranes, they can enter cells with the help of transfection reagents via facilitated transport. Inside cells, however, they can still be hydrolyzed by cytoplasmic RNases before reaching their target. Here we show that poly-2'- O-(2,4-dinitrophenyl)-siRNA (DNP-siRNA) can by itself diffuse into mammalian cells and stay in the cells for several days, with no detectable degradation. Using the DNP-RNA targeting to the insulin-like growth factor receptor (IGF-IR) as an example, we demonstrate that the efficacy of this DNP-siRNA for inhibiting the growth of three different types of tumor cells is several-fold higher than that of the corresponding native siRNA. Similar results were obtained from Western blotting assay. As expected, the control siRNAs with mismatched, scrambled, and reverse sequences are all inactive. These results illustrate that both the biomembrane permeability and intracellular stability of siRNA can be greatly improved by DNP derivatization without loss of its sequence specificity.

Citing Articles

The emerging potential of siRNA nanotherapeutics in treatment of arthritis.

Kumari A, Kaur A, Aggarwal G Asian J Pharm Sci. 2023; 18(5):100845.

PMID: 37881798 PMC: 10594572. DOI: 10.1016/j.ajps.2023.100845.


Effect of the array of amines on the transfection efficiency of cationic peptidomimetic lipid molecules into neural cells.

Yu X, Xiao H, Muqier M, Han S, Baigude H RSC Adv. 2022; 12(33):21567-21573.

PMID: 35975061 PMC: 9346625. DOI: 10.1039/d2ra03347j.


RNA interference as a novel treatment strategy for chronic hepatitis B infection.

Hui R, Mak L, Seto W, Yuen M Clin Mol Hepatol. 2022; 28(3):408-424.

PMID: 35172540 PMC: 9293617. DOI: 10.3350/cmh.2022.0012.


Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.

Sajid M, Moazzam M, Kato S, Yeseom Cho K, Tiwari R Pharmaceuticals (Basel). 2020; 13(10).

PMID: 33036435 PMC: 7600125. DOI: 10.3390/ph13100294.


Innovative approaches for cancer treatment: current perspectives and new challenges.

Pucci C, Martinelli C, Ciofani G Ecancermedicalscience. 2019; 13:961.

PMID: 31537986 PMC: 6753017. DOI: 10.3332/ecancer.2019.961.